Skip to main content
TipRanks
Go Ultimate75% OFF

Koninklijke Philips (PHG) Q3 2026 Earnings Report

633 Followers

PHG Q3 2026 EPS Results

Actual EPS
$0.45
Consensus EPS
$0.39
Beat/Miss
Beat by +$0.06
One Year Ago EPS
$0.41

PHG Q3 2026 Revenue Results

Actual Revenue
$5.05B
Expected Revenue
$5.01B
Beat/Miss
Beat by +$46.82M
YoY Revenue Growth
+0.53%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/03/2026
Time
Before Open
Conference Call
Tuesday, November 3, 2026
PHG Upcoming Earnings

Koninklijke Philips's next earnings date is estimated for February 1, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

PHG Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 03, 2026|% Change Since:8.05%|
Earnings Call Sentiment|Positive

The call was predominantly positive. Philips reported strong order momentum, broad-based Personal Health growth, margin expansion ahead of expectations, improved free cash flow, productivity savings, deleveraging and reiterated full-year guidance. The main challenges were flat Diagnosis & Treatment sales caused partly by ultrasound delays, cautious conditions and pricing pressure in China, lower Connected Care order intake due to longer deal cycles, cost inflation, tariffs and ongoing Respironics-related legal matters. Management expressed confidence in the current-year outlook and the medium-term trajectory.

Company Guidance

Philips reiterated its full year comparable sales growth outlook of 3% to 4.5%, with Diagnosis & Treatment expected to deliver comparable sales growth at the upper end of the low single-digit range, Connected Care within the 3% to 4.5% range and Personal Health at the lower end of the high single-digit growth rate; adjusted EBITA margin remains 13.5% to 14%, including a U.S. tariff refund benefit of approximately 1%, and free cash flow remains EUR 1.5 billion to EUR 1.7 billion, including a net U.S. tariff refund benefit of approximately EUR 200 million. The outlook includes currently known tariffs and assumes payment of the U.S. DOJ settlement in the first quarter of 2027, subject to finalization of the relevant documentation, and excludes other ongoing Philips Respironics related proceedings, including the investigation by the U.S. State Attorneys General. Philips continues to expect China sales to be broadly stable for the full year, with growth in Personal Health offsetting a decline in health system businesses, and expects full year input cost pressures at the high double-digit million euros at group level. The company also reiterated its mid-single-digit comparable sales growth CAGR over '26 to '28 and a mid-teen adjusted EBITA margin by 2028, with a EUR 1.5 billion productivity savings target by the end of 2028.

  • Strong Q3 Order Intake and Sales GrowthOrder intake grew 8%, driven by sustained customer demand and recently launched innovations. Comparable sales increased approximately 3%, supported by strength in Personal Health and Connected Care.
  • Margin Expansion Ahead of ExpectationsGroup adjusted EBITA margin increased 70 basis points year-on-year to 13%, ahead of expectations, with margin expansion across all three business segments. Higher sales, improved gross margin, higher-margin innovations, productivity measures and a modest benefit from more favorable tariff rates more than offset higher cost inflation.
  • Strong Free Cash Flow and Earnings GrowthFree cash flow was an inflow of EUR 384 million, compared with EUR 172 million in Q3 last year, mainly driven by higher cash earnings and lower working capital outflows. Adjusted EPS increased more than 10% year-on-year to EUR 0.40.
  • Diagnosis & Treatment Order MomentumDiagnosis & Treatment order intake growth approached 20%, with double-digit growth in both Image-Guided Therapy and Precision Diagnosis. The Precision Diagnosis order book expanded for three consecutive quarters, reaching a stated turning point in its rebuilding.
  • Image-Guided Therapy Wins and Market Share OpportunityImage-Guided Therapy delivered sustained order growth, particularly in North America, where Philips secured vendor-of-choice positions at major U.S. health systems despite competitors having relationships of more than a decade. Philips said this is creating opportunities to dislodge incumbents and expand its installed base.
  • Imaging Innovation Gaining TractionThe Spectral CT platform order book grew double digits year-on-year, with Verida becoming an increasingly meaningful contributor. The CT 5300 order book nearly doubled year-on-year, while helium-free BlueSeal MR systems delivered strong order growth and represented around 70% of MR systems shipped year-to-date.
  • Connected Care Revenue and Recurring Revenue GrowthConnected Care comparable sales grew 5%. Monitoring delivered mid-single-digit comparable sales growth, Sleep & Respiratory Care growth accelerated to mid-single digits, and Enterprise Informatics delivered high single-digit sales growth. Enterprise Monitoring as a Service revenue nearly doubled year-on-year.
  • Connected Care Margin ImprovementConnected Care adjusted EBITA margin increased 190 basis points year-on-year to 13.3%. Excluding a 150 basis point prior-year gain from the remeasurement of a minority investment, margin expanded 340 basis points, driven by higher sales, higher gross margin, favorable mix and productivity measures.
  • Personal Health Broad-Based Growth and Market Share GainsPersonal Health comparable sales grew 8%, with growth across all three businesses and all regions, building on double-digit growth in the prior-year quarter. Philips reported sustained market share gains, strong sellout trends and growth driven by premium shavers, OneBlade, Sonicare and Avent.
  • Personal Health Outlook RaisedPhilips increased its Personal Health full-year guidance to the lower end of the high single-digit growth rate, citing continued strength and breadth of performance across businesses and regions, category leadership, innovation, premiumization and commercial execution.
  • Productivity Program ProgressThe productivity program delivered EUR 170 million in savings in Q3 and EUR 427 million year-to-date. Philips remains on track to achieve its EUR 1.5 billion savings target by the end of 2028 and is extending the program by embedding AI in operational workflows, customer service and R&D.
  • Balance Sheet Deleveraging and Green Bond DemandNet debt to adjusted EBITA declined to 1.7x from 2.2x a year ago, while Philips closed Q3 with EUR 2.8 billion in cash and EUR 5.4 billion in net debt. The company issued a EUR 650 million EU Green Bond that was 2.7x oversubscribed and was the health care industry's first bond under the new European Green Bond Standard.
  • Full-Year Guidance ReiteratedPhilips reiterated full-year comparable sales growth guidance of 3% to 4.5%, adjusted EBITA margin guidance of 13.5% to 14%, including a U.S. tariff refund benefit of approximately 1%, and free cash flow guidance of EUR 1.5 billion to EUR 1.7 billion, including a net U.S. tariff refund benefit of approximately EUR 200 million.
  • Innovation and External FundingPhilips is investing EUR 50 million in AI, robotics and advanced imaging in the Netherlands, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing. An ARPA-H award of up to $34 million will support AI-enabled robotic stroke care on the Azurion platform.
  • Supply Chain Reliability ImprovementsDespite geopolitical uncertainty and increasing demand for electronic components, including from AI infrastructure, service levels improved further year-on-year. Philips continued dual sourcing, expanded its supplier network, regionalized and selectively localized its supply chain, and opened a new parts distribution center in Jakarta.
  • Positive Regional Demand Outside ChinaHospital demand was strong across North America and international regions. Order intake remained robust in Europe, while demand was particularly strong in Latin America, India and Asia Pacific. Philips expects North America to remain a core growth engine and Europe to become an increasingly important contributor to growth.
  • Progress on Respironics Legal ProceedingsPhilips said the agreement in principle between Respironics and the U.S. Department of Justice marks an important step in resolving consequences of the Sleep & Respiratory Care recall. The company also said the recall was finalized in September and that Sleep & Respiratory Care profitability continued to improve, with double-digit margins.

PHG Earnings History

PHG earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 01, 20272026 (Q4)0.64-0.71――
Nov 03, 20262026 (Q3)0.390.450.418.21% (+0.03)
Jul 27, 20262026 (Q2)0.400.560.4134.46% (+0.14)
May 06, 20262026 (Q1)0.230.270.28-4.93% (-0.01)
Feb 10, 20262025 (Q4)0.560.710.5334.40% (+0.18)
Nov 04, 20252025 (Q3)0.370.410.3422.49% (+0.08)
Jul 29, 20252025 (Q2)0.320.410.3228.09% (+0.09)
May 06, 20252025 (Q1)0.200.280.275.58% (+0.01)
Feb 19, 20252024 (Q4)0.570.530.4324.88% (+0.11)
Oct 28, 20242024 (Q3)0.440.340.340.00% (+0.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed